Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine

A virus-like particle (VLP) comprising

• at least one human metapneumovirus (hMPV) matrix (M) protein;
• and
• a prefusion surface respiratory syncytial virus (RSV) F protein and a postfusion RSV F protein, wherein transmembrane and cytoplasmic domains of the prefusion and postfusion RSV F proteins are replaced with analogous amino acid sequences from an hMPV F protein, wherein the prefusion RSV F protein comprises the following substitutions relative to SEQ ID NO:
• 1:
• A102C, I148C, S155C and S290C, and wherein the prefusion RSV F protein is modified at both of furin cleavage site RARR at residues 106 to 109 of SEQ ID NO:
• 1 to KAHQ of SEQ ID NO:
• 5 and furin cleavage site RKRR at residues 133 to 136 of SEQ ID NO:
• 1 to KKQH of SEQ ID NO:
• 7.